Jennifer L. Brogdon

3 ta ish

Novartis (United States)

1. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

   Donald M. O’Rourke, MacLean P. Nasrallah, Arati Desai +18

   MaqolaOAOchiq kirish20174 iqtibos

   ABIABI:AkademIndex/2026.other.020482

2. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

   Joseph A. Fraietta, Simon F. Lacey, Elena J. Orlando +34

   MaqolaOAOchiq kirish20182 iqtibos

   ABIABI:AkademIndex/2026.other.020493

3. Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial

   Stephen Bagley, Zev A. Binder, Lamia Lamrani +32

   MaqolaOAOchiq kirish20242 iqtibos

   ABIABI:AkademIndex/2026.other.102955